The matter at hand in Connelly v. IRS before the US Supreme Court may seem straightforward at first glance: should life-insurance proceedings be incorporated into the value of a decedent’s company for tax considerations? Upon closer examination, however, it becomes apparent that this issue is multifaceted, and several questions will persist irrespective of the court’s ruling.
A closely held corporation claimed life-insurance policy proceeds to facilitate the redemption of the shareholder’s stock. The question raised is whether this should be taken as a corporate asset when assessing the value of the shareholder’s shares for federal estate tax implications.
The taxpayer argues that the life-insurance proceeds should not be included, which would lower the value of the decedent’s shares and thus decrease the tax liability. Nonetheless, the IRS disagreed, resulting in additional estate taxes assessment exceeding $1 million. This assessment was backed up by the US Court of Appeals of the Eighth Circuit, which upheld a district court’s ruling siding with the IRS. The Supreme Court began to hear arguments on this case on March 27.
These proceedings highlight several issues that the courts have not directly addressed. For instance, it remains uncertain whether a valuation should factor in the death of a decedent: at what exact moment should the valuation take place – just before death, exactly at the moment of death, or just after?
These seemingly minute details hold significant implications. For instance, if the valuation occurred before death or at the moment of death (presumably an unpredictable event), there would be no anticipation of an immediate payout from the life-insurance proceeds. However, if post-death timing is used for the valuation, various consequences of the death should, perhaps, be considered.
Furthermore, it remains unclear whether factors like age and health status of the insured should play a role in the analysis, and, if a company benefits from multiple life insurance policies, does that elevate the company’s value?
The Connelly case brought up the question of whether life insurance proceeds – the death benefit – should be factored into the company’s value. However, there was no consideration regarding whether another measure of value, such as cash surrender value or interpolated terminal reserve value, should be applied instead.
The forthcoming Supreme Court ruling in Connelly v. United States will undoubtedly present invaluable insights. However, legal professionals and appraisers must continue seeking input from estate planners and litigators when encountering these unanswered questions in estate valuation.